A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma

Leukemia and Lymphoma

Volumn 55, Issue 9, 2014, Pages 2013-2017

  Jourdan, Eric ^a   Leblond, Veronique ^b   Maisonneuve, Hervé ^c   Benhadji, Karim A ^d   Hossain, Anwar M ^d   Nguyen, Tuan S ^d   Wooldridge, James E ^d   Moreau, Philippe ^e  

^a NÎMES UNIVERSITY HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Centre territorial d'evaluation et de traitement de la douleur   (France)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITÉ DE NANTES   (France)

Author keywords

Enzastaurin; Multiple myeloma; Phase II; Serine threonine kinase inhibitor

Indexed keywords

BIOLOGICAL MARKER; DEXAMETHASONE; ENZASTAURIN; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; LOADING DRUG DOSE; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; MIDDLE AGED; RETREATMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; RETREATMENT; TREATMENT OUTCOME;

EID: 84904442676     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.861066     Document Type: Article

References (29)

1. Landis SH, Murray T, B olden S, W ingo P A. C ancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-31.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
3. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
4. Milhelic R, Kaufman JL, Lonial S. Maintenance therapYin multiple myeloma. Leukemia 2007; 21: 1150-1157.
5. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001; 10: 2117-2140.
6. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKCbeta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005; 18: 1377-1384.
7. Graff J R, M cNulty A M, H anna K R, et al. The protein kinase Cbetaselective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-7469.
8. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma:in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007; 109: 1669-1677.
9. R izvi M A, G hias K, D avies K M, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006; 5: 1783-1789.
10. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activitYin Waldenstrom macroglobulinemia. Blood 2007; 109: 4964-4972.
11. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006; 24: 4092-4099.
12. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-1746.
13. M orschhauser F, S eymour J F, K luin-Nelemans H C, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008; 19: 247-253.
14. Hanauske AR, Lahn M, Musib LC, et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009; 20: 1565-1575.
15. Hainsworth JD, Arrowsmith AE, McCleod M, et al. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the firstline treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): preliminary analysis. J Clin Oncol 2011; 29(Suppl.): Abstract 8016.
16. Schwartzberg L, Hermann R, Flinn IW, et al. Phase II study of enzastaurin in patients with follicular lymphoma: updated final clinical results and immunohistochemical correlations. Blood 2012; 120(Suppl. 1): Abstract 777.
17. Ghobrial IM, Moreau P, Harris B, et al. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstr ö m Macroglobulinemia. Clin Cancer Res 2012; 18: 5043-5050.
18. V ELCADE [package insert]. C ambridge, MA: Millennium Pharmaceuticals; 2012.
19. REVLIMID [package insert]. S ummit, NJ: Celgene Corporation;
20. Blad é J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
21. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activitYin Waldenstrom macroglobulinemia. Blood 2007; 109: 4964-4972.
22. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
23. Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008; 141: 41-51.
24. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011; 118: 2970-2975.
25. S iegel D S, M artin T, W ang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
26. P odar K, T ai Y T, D avies F E, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428-435.
27. Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factorinduced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 2002; 277: 7875-7881.
28. Zhang J, Sattler M, Tonon G, et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathwaYin multiple myeloma. Cancer Res 2009; 69: 5082-5090.
29. Ghobrial IM, Munshi NC, Harris BN, et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011; 86: 573-578.